View in EDS

Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.

Saved in:
Bibliographic Details
Title: Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
Authors: Valgimigli, Marco, Frigoli, Enrico, Leonardi, Sergio, Vranckx, Pascal, Rothenbühler, Martina, Tebaldi, Matteo, Varbella, Ferdinando, Calabrò, Paolo, Garducci, Stefano, Rubartelli, Paolo, Briguori, Carlo, Andó, Giuseppe, Ferrario, Maurizio, Limbruno, Ugo, Garbo, Roberto, Sganzerla, Paolo, Russo, Filippo, Nazzaro, Marco, Lupi, Alessandro, Cortese, Bernardo
Source: Lancet. 9/8/2018, Vol. 392 Issue 10150, p835-848. 14p.
Subjects: Heparin, Treatment of acute coronary syndrome, Randomized controlled trials, Percutaneous coronary intervention, Femoral artery, Anticoagulants, Cardiovascular system, Comparative studies, Glycoproteins, Hemorrhage, Research methodology, Medical care, Medical cooperation, Mortality, Myocardial infarction, Peptides, Complications of prosthesis, Proteins, Recombinant proteins, Research, Surgical stents, Stroke, Evaluation research, Acute coronary syndrome, Radial artery, Hirudin, Coronary angiography, Perioperative care, Chemical inhibitors, Disease complications
Abstract: Background: The Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) programme was designed to assess the comparative safety and effectiveness of radial versus femoral access and of bivalirudin versus unfractionated heparin with optional glycoprotein IIb/IIIa inhibitors in patients with the whole spectrum of acute coronary syndrome undergoing invasive management. Here we describe the prespecified final 1-year outcomes of the entire programme.Methods: MATRIX was a programme of three nested, randomised, multicentre, open-label, superiority trials in patients with acute coronary syndrome in 78 hospitals in Italy, the Netherlands, Spain, and Sweden. Patients with ST-elevation myocardial infarction were simultaneously randomly assigned (1:1) before coronary angiography to radial or femoral access and to bivalirudin, with or without post-percutaneous coronary intervention infusion or unfractionated heparin (one-step inclusion). Patients with non-ST-elevation acute coronary syndrome were randomly assigned (1:1) before coronary angiography to radial or femoral access and, only if deemed eligible to percutaneous coronary intervention after angiography (two-step inclusion), entered the antithrombin type and treatment duration programmes. Randomisation sequences were computer generated, blocked, and stratified by intended new or current use of P2Y12 inhibitor (clopidogrel vs ticagrelor or prasugrel), and acute coronary syndrome type (ST-elevation myocardial infarction, troponin-positive, or troponin-negative non-ST-elevation acute coronary syndrome). Bivalirudin was given as a bolus of 0·75 mg/kg, followed immediately by an infusion of 1·75 mg/kg per h until completion of percutaneous coronary intervention. Heparin was given at 70-100 units per kg in patients not receiving glycoprotein IIb/IIIa inhibitors, and at 50-70 units per kg in patients receiving glycoprotein IIb/IIIa inhibitors. Clinical follow-up was done at 30 days and 1 year. Co-primary outcomes for MATRIX access and MATRIX antithrombin type were major adverse cardiovascular events, defined as the composite of all-cause mortality, myocardial infarction, or stroke up to 30 days; and net adverse clinical events, defined as the composite of non-coronary artery bypass graft-related major bleeding, or major adverse cardiovascular events up to 30 days. The primary outcome for MATRIX treatment duration was the composite of urgent target vessel revascularisation, definite stent thrombosis, or net adverse clinical events up to 30 days. Analyses were done according to the intention-to-treat principle. This trial is registered with ClinicalTrials.gov, number NCT01433627.Findings: Between Oct 11, 2011, and Nov 7, 2014, we randomly assigned 8404 patients to receive radial (4197 patients) or femoral (4207 patients) access. Of these 8404 patients, 7213 were included in the MATRIX antithrombin type study and were randomly assigned to bivalirudin (3610 patients) or heparin (3603 patients). Patients assigned to bivalirudin were included in the MATRIX treatment duration study, and were randomly assigned to post-procedure infusion (1799 patients) or no post-procedure infusion (1811 patients). At 1 year, major adverse cardiovascular events did not differ between patients assigned to radial access compared with those assigned to femoral access (14·2% vs 15·7%; rate ratio 0·89, 95% CI 0·80-1·00; p=0·0526), but net adverse clinical events were fewer with radial than with femoral access (15·2% vs 17·2%; 0·87, 0·78-0·97; p=0·0128). Compared with heparin, bivalirudin was not associated with fewer major adverse cardiovascular (15·8% vs 16·8%; 0·94, 0·83-1·05; p=0·28) or net adverse clinical events (17·0% vs 18·4%; 0·91, 0·81-1·02; p=0·10). The composite of urgent target vessel revascularisation, stent thrombosis, or net adverse clinical events did not differ with or without post-procedure bivalirudin infusion (17·4% vs 17·4%; 0·99, 0·84-1·16; p=0·90).Interpretation: In patients with acute coronary syndrome, radial access was associated with lower rates of net adverse clinical events compared with femoral access, but not major adverse cardiovascular events at 1 year. Bivalirudin with or without post-procedure infusion was not associated with lower rates of major adverse cardiovascular events or net adverse clinical events. Radial access should become the default approach in acute coronary syndrome patients undergoing invasive management.Funding: Italian Society of Invasive Cardiology, The Medicines Company, Terumo, amd Canada Research Chairs Programme. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 131745907
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Valgimigli%2C+Marco%22">Valgimigli, Marco</searchLink><br /><searchLink fieldCode="AR" term="%22Frigoli%2C+Enrico%22">Frigoli, Enrico</searchLink><br /><searchLink fieldCode="AR" term="%22Leonardi%2C+Sergio%22">Leonardi, Sergio</searchLink><br /><searchLink fieldCode="AR" term="%22Vranckx%2C+Pascal%22">Vranckx, Pascal</searchLink><br /><searchLink fieldCode="AR" term="%22Rothenbühler%2C+Martina%22">Rothenbühler, Martina</searchLink><br /><searchLink fieldCode="AR" term="%22Tebaldi%2C+Matteo%22">Tebaldi, Matteo</searchLink><br /><searchLink fieldCode="AR" term="%22Varbella%2C+Ferdinando%22">Varbella, Ferdinando</searchLink><br /><searchLink fieldCode="AR" term="%22Calabrò%2C+Paolo%22">Calabrò, Paolo</searchLink><br /><searchLink fieldCode="AR" term="%22Garducci%2C+Stefano%22">Garducci, Stefano</searchLink><br /><searchLink fieldCode="AR" term="%22Rubartelli%2C+Paolo%22">Rubartelli, Paolo</searchLink><br /><searchLink fieldCode="AR" term="%22Briguori%2C+Carlo%22">Briguori, Carlo</searchLink><br /><searchLink fieldCode="AR" term="%22Andó%2C+Giuseppe%22">Andó, Giuseppe</searchLink><br /><searchLink fieldCode="AR" term="%22Ferrario%2C+Maurizio%22">Ferrario, Maurizio</searchLink><br /><searchLink fieldCode="AR" term="%22Limbruno%2C+Ugo%22">Limbruno, Ugo</searchLink><br /><searchLink fieldCode="AR" term="%22Garbo%2C+Roberto%22">Garbo, Roberto</searchLink><br /><searchLink fieldCode="AR" term="%22Sganzerla%2C+Paolo%22">Sganzerla, Paolo</searchLink><br /><searchLink fieldCode="AR" term="%22Russo%2C+Filippo%22">Russo, Filippo</searchLink><br /><searchLink fieldCode="AR" term="%22Nazzaro%2C+Marco%22">Nazzaro, Marco</searchLink><br /><searchLink fieldCode="AR" term="%22Lupi%2C+Alessandro%22">Lupi, Alessandro</searchLink><br /><searchLink fieldCode="AR" term="%22Cortese%2C+Bernardo%22">Cortese, Bernardo</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 9/8/2018, Vol. 392 Issue 10150, p835-848. 14p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Heparin%22">Heparin</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+of+acute+coronary+syndrome%22">Treatment of acute coronary syndrome</searchLink><br /><searchLink fieldCode="DE" term="%22Randomized+controlled+trials%22">Randomized controlled trials</searchLink><br /><searchLink fieldCode="DE" term="%22Percutaneous+coronary+intervention%22">Percutaneous coronary intervention</searchLink><br /><searchLink fieldCode="DE" term="%22Femoral+artery%22">Femoral artery</searchLink><br /><searchLink fieldCode="DE" term="%22Anticoagulants%22">Anticoagulants</searchLink><br /><searchLink fieldCode="DE" term="%22Cardiovascular+system%22">Cardiovascular system</searchLink><br /><searchLink fieldCode="DE" term="%22Comparative+studies%22">Comparative studies</searchLink><br /><searchLink fieldCode="DE" term="%22Glycoproteins%22">Glycoproteins</searchLink><br /><searchLink fieldCode="DE" term="%22Hemorrhage%22">Hemorrhage</searchLink><br /><searchLink fieldCode="DE" term="%22Research+methodology%22">Research methodology</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+care%22">Medical care</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+cooperation%22">Medical cooperation</searchLink><br /><searchLink fieldCode="DE" term="%22Mortality%22">Mortality</searchLink><br /><searchLink fieldCode="DE" term="%22Myocardial+infarction%22">Myocardial infarction</searchLink><br /><searchLink fieldCode="DE" term="%22Peptides%22">Peptides</searchLink><br /><searchLink fieldCode="DE" term="%22Complications+of+prosthesis%22">Complications of prosthesis</searchLink><br /><searchLink fieldCode="DE" term="%22Proteins%22">Proteins</searchLink><br /><searchLink fieldCode="DE" term="%22Recombinant+proteins%22">Recombinant proteins</searchLink><br /><searchLink fieldCode="DE" term="%22Research%22">Research</searchLink><br /><searchLink fieldCode="DE" term="%22Surgical+stents%22">Surgical stents</searchLink><br /><searchLink fieldCode="DE" term="%22Stroke%22">Stroke</searchLink><br /><searchLink fieldCode="DE" term="%22Evaluation+research%22">Evaluation research</searchLink><br /><searchLink fieldCode="DE" term="%22Acute+coronary+syndrome%22">Acute coronary syndrome</searchLink><br /><searchLink fieldCode="DE" term="%22Radial+artery%22">Radial artery</searchLink><br /><searchLink fieldCode="DE" term="%22Hirudin%22">Hirudin</searchLink><br /><searchLink fieldCode="DE" term="%22Coronary+angiography%22">Coronary angiography</searchLink><br /><searchLink fieldCode="DE" term="%22Perioperative+care%22">Perioperative care</searchLink><br /><searchLink fieldCode="DE" term="%22Chemical+inhibitors%22">Chemical inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22Disease+complications%22">Disease complications</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>The Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) programme was designed to assess the comparative safety and effectiveness of radial versus femoral access and of bivalirudin versus unfractionated heparin with optional glycoprotein IIb/IIIa inhibitors in patients with the whole spectrum of acute coronary syndrome undergoing invasive management. Here we describe the prespecified final 1-year outcomes of the entire programme.<bold>Methods: </bold>MATRIX was a programme of three nested, randomised, multicentre, open-label, superiority trials in patients with acute coronary syndrome in 78 hospitals in Italy, the Netherlands, Spain, and Sweden. Patients with ST-elevation myocardial infarction were simultaneously randomly assigned (1:1) before coronary angiography to radial or femoral access and to bivalirudin, with or without post-percutaneous coronary intervention infusion or unfractionated heparin (one-step inclusion). Patients with non-ST-elevation acute coronary syndrome were randomly assigned (1:1) before coronary angiography to radial or femoral access and, only if deemed eligible to percutaneous coronary intervention after angiography (two-step inclusion), entered the antithrombin type and treatment duration programmes. Randomisation sequences were computer generated, blocked, and stratified by intended new or current use of P2Y12 inhibitor (clopidogrel vs ticagrelor or prasugrel), and acute coronary syndrome type (ST-elevation myocardial infarction, troponin-positive, or troponin-negative non-ST-elevation acute coronary syndrome). Bivalirudin was given as a bolus of 0·75 mg/kg, followed immediately by an infusion of 1·75 mg/kg per h until completion of percutaneous coronary intervention. Heparin was given at 70-100 units per kg in patients not receiving glycoprotein IIb/IIIa inhibitors, and at 50-70 units per kg in patients receiving glycoprotein IIb/IIIa inhibitors. Clinical follow-up was done at 30 days and 1 year. Co-primary outcomes for MATRIX access and MATRIX antithrombin type were major adverse cardiovascular events, defined as the composite of all-cause mortality, myocardial infarction, or stroke up to 30 days; and net adverse clinical events, defined as the composite of non-coronary artery bypass graft-related major bleeding, or major adverse cardiovascular events up to 30 days. The primary outcome for MATRIX treatment duration was the composite of urgent target vessel revascularisation, definite stent thrombosis, or net adverse clinical events up to 30 days. Analyses were done according to the intention-to-treat principle. This trial is registered with ClinicalTrials.gov, number NCT01433627.<bold>Findings: </bold>Between Oct 11, 2011, and Nov 7, 2014, we randomly assigned 8404 patients to receive radial (4197 patients) or femoral (4207 patients) access. Of these 8404 patients, 7213 were included in the MATRIX antithrombin type study and were randomly assigned to bivalirudin (3610 patients) or heparin (3603 patients). Patients assigned to bivalirudin were included in the MATRIX treatment duration study, and were randomly assigned to post-procedure infusion (1799 patients) or no post-procedure infusion (1811 patients). At 1 year, major adverse cardiovascular events did not differ between patients assigned to radial access compared with those assigned to femoral access (14·2% vs 15·7%; rate ratio 0·89, 95% CI 0·80-1·00; p=0·0526), but net adverse clinical events were fewer with radial than with femoral access (15·2% vs 17·2%; 0·87, 0·78-0·97; p=0·0128). Compared with heparin, bivalirudin was not associated with fewer major adverse cardiovascular (15·8% vs 16·8%; 0·94, 0·83-1·05; p=0·28) or net adverse clinical events (17·0% vs 18·4%; 0·91, 0·81-1·02; p=0·10). The composite of urgent target vessel revascularisation, stent thrombosis, or net adverse clinical events did not differ with or without post-procedure bivalirudin infusion (17·4% vs 17·4%; 0·99, 0·84-1·16; p=0·90).<bold>Interpretation: </bold>In patients with acute coronary syndrome, radial access was associated with lower rates of net adverse clinical events compared with femoral access, but not major adverse cardiovascular events at 1 year. Bivalirudin with or without post-procedure infusion was not associated with lower rates of major adverse cardiovascular events or net adverse clinical events. Radial access should become the default approach in acute coronary syndrome patients undergoing invasive management.<bold>Funding: </bold>Italian Society of Invasive Cardiology, The Medicines Company, Terumo, amd Canada Research Chairs Programme. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=131745907
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(18)31714-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 14
        StartPage: 835
    Subjects:
      – SubjectFull: Heparin
        Type: general
      – SubjectFull: Treatment of acute coronary syndrome
        Type: general
      – SubjectFull: Randomized controlled trials
        Type: general
      – SubjectFull: Percutaneous coronary intervention
        Type: general
      – SubjectFull: Femoral artery
        Type: general
      – SubjectFull: Anticoagulants
        Type: general
      – SubjectFull: Cardiovascular system
        Type: general
      – SubjectFull: Comparative studies
        Type: general
      – SubjectFull: Glycoproteins
        Type: general
      – SubjectFull: Hemorrhage
        Type: general
      – SubjectFull: Research methodology
        Type: general
      – SubjectFull: Medical care
        Type: general
      – SubjectFull: Medical cooperation
        Type: general
      – SubjectFull: Mortality
        Type: general
      – SubjectFull: Myocardial infarction
        Type: general
      – SubjectFull: Peptides
        Type: general
      – SubjectFull: Complications of prosthesis
        Type: general
      – SubjectFull: Proteins
        Type: general
      – SubjectFull: Recombinant proteins
        Type: general
      – SubjectFull: Research
        Type: general
      – SubjectFull: Surgical stents
        Type: general
      – SubjectFull: Stroke
        Type: general
      – SubjectFull: Evaluation research
        Type: general
      – SubjectFull: Acute coronary syndrome
        Type: general
      – SubjectFull: Radial artery
        Type: general
      – SubjectFull: Hirudin
        Type: general
      – SubjectFull: Coronary angiography
        Type: general
      – SubjectFull: Perioperative care
        Type: general
      – SubjectFull: Chemical inhibitors
        Type: general
      – SubjectFull: Disease complications
        Type: general
    Titles:
      – TitleFull: Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Valgimigli, Marco
      – PersonEntity:
          Name:
            NameFull: Frigoli, Enrico
      – PersonEntity:
          Name:
            NameFull: Leonardi, Sergio
      – PersonEntity:
          Name:
            NameFull: Vranckx, Pascal
      – PersonEntity:
          Name:
            NameFull: Rothenbühler, Martina
      – PersonEntity:
          Name:
            NameFull: Tebaldi, Matteo
      – PersonEntity:
          Name:
            NameFull: Varbella, Ferdinando
      – PersonEntity:
          Name:
            NameFull: Calabrò, Paolo
      – PersonEntity:
          Name:
            NameFull: Garducci, Stefano
      – PersonEntity:
          Name:
            NameFull: Rubartelli, Paolo
      – PersonEntity:
          Name:
            NameFull: Briguori, Carlo
      – PersonEntity:
          Name:
            NameFull: Andó, Giuseppe
      – PersonEntity:
          Name:
            NameFull: Ferrario, Maurizio
      – PersonEntity:
          Name:
            NameFull: Limbruno, Ugo
      – PersonEntity:
          Name:
            NameFull: Garbo, Roberto
      – PersonEntity:
          Name:
            NameFull: Sganzerla, Paolo
      – PersonEntity:
          Name:
            NameFull: Russo, Filippo
      – PersonEntity:
          Name:
            NameFull: Nazzaro, Marco
      – PersonEntity:
          Name:
            NameFull: Lupi, Alessandro
      – PersonEntity:
          Name:
            NameFull: Cortese, Bernardo
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 08
              M: 09
              Text: 9/8/2018
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 392
            – Type: issue
              Value: 10150
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1